Oncolytics Biotech Inc. Reports 33% Response Rate for Pelareorep in Colorectal Cancer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 07 2026
0mins
Source: Newsfilter
- Market Potential: The global cancer drugs market is projected to reach $594.3 billion by 2035, with high-tech immunotherapies replacing traditional chemotherapy, positioning Oncolytics Biotech Inc. as a key player in this transformation.
- Clinical Data Breakthrough: Oncolytics' pelareorep achieved a 33% objective response rate in second-line KRAS-mutant microsatellite-stable metastatic colorectal cancer patients when combined with standard chemotherapy, significantly surpassing the historical 6-11% response rate for chemotherapy alone, potentially driving growth in a $20 billion market.
- Enhanced Expert Validation: Oncolytics expanded its Gastrointestinal Tumor Scientific Advisory Board with three globally recognized experts, further elevating the academic validation and industry attention for pelareorep, which may attract more investment and collaboration opportunities.
- Successful FDA Alignment: Oncolytics has secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, marking the launch of the only immunotherapy registration trial planned for this disease, thereby enhancing its market competitiveness.
Analyst Views on ONCY
Wall Street analysts forecast ONCY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ONCY is 5.50 USD with a low forecast of 3.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.130
Low
3.00
Averages
5.50
High
10.00
Current: 1.130
Low
3.00
Averages
5.50
High
10.00
About ONCY
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The Company is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
